**MARKET SIZE**

**Indian Pharmaceutical Market (US$ billion)**

<table>
<thead>
<tr>
<th>Year</th>
<th>2021</th>
<th>2024</th>
<th>2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>42.0</td>
<td>65.0</td>
<td>120.0</td>
</tr>
</tbody>
</table>

**SECTOR COMPOSITION**

<table>
<thead>
<tr>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
<th>FY21</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.9</td>
<td>8.7</td>
<td>8.5</td>
<td>8.6</td>
<td>8.4</td>
<td>7.2</td>
</tr>
</tbody>
</table>

**Note:** *Top 10 companies as per research by HDFC Securities*

**KEY TRENDS**

- **Cost Efficiency:** Low cost of production and R&D boost efficiency of Indian pharma companies, leading to competitive export.
- **Economic Drivers:** High economic growth along with increasing penetration of health insurance to push expenditure on healthcare and medicine in India.
- **Policy support:** In June 2021, Finance Minister Ms. Nirmala Sitharaman announced an additional outlay of Rs. 197,000 crore (US$ 26,578.3 million) that will be utilised over five years for the pharmaceutical PLI scheme in 13 key sectors such as active pharmaceutical ingredients, drug intermediaries and key starting materials.
- **Increasing Investments:** The FDI inflows in the Indian drugs and pharmaceuticals sector reached US$ 19.90 billion between April 2000-June 2022.

**GOVERNMENT INITIATIVES**

- Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
- Government Expenditure on Health in India (US$ billion)

**Pharmaceutical Export from India (US$ billion)**

<table>
<thead>
<tr>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
<th>FY21</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.9</td>
<td>16.8</td>
<td>17.3</td>
<td>19.1</td>
<td>20.7</td>
<td>22.4</td>
</tr>
</tbody>
</table>

**Government Expenditure on Health in India (US$ billion)**

- FY16: 41.4
- FY17: 46.0
- FY18: 41.4
- FY19: 34.9
- FY20: 35.1
- FY21: 23.6

**ADVANTAGE INDIA**

- COVID BEEP
- National Health Policy